Invesco
SNDX icon

Invesco’s Syndax Pharmaceuticals SNDX Stock Holding History

Invesco’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.9M Buy
252,761
+92,236
+57% +$2M ﹤0.01% 2114
2025
Q4 		$3.37M Buy
160,525
+27,434
+21% +$479K ﹤0.01% 2413
2025
Q3 		$2.05M Buy
133,091
+27,934
+27% +$366K ﹤0.01% 2601
2025
Q2 		$985K Buy
105,157
+28,309
+37% +$312K ﹤0.01% 2847
2025
Q1 		$944K Buy
76,848
+25,524
+50% +$360K ﹤0.01% 2858
2024
Q4 		$679K Buy
51,324
+684
+1% +$11.7K ﹤0.01% 3099
2024
Q3 		$975K Buy
50,640
+579
+1% +$12K ﹤0.01% 2915
2024
Q2 		$1.03M Buy
50,061
+1,226
+3% +$25.7K ﹤0.01% 2912
2024
Q1 		$1.16M Buy
48,835
+19,515
+67% +$435K ﹤0.01% 2924
2023
Q4 		$634K Sell
29,320
-7,223
-20% -$111K ﹤0.01% 3098
2023
Q3 		$531K Buy
36,543
+6,095
+20% +$115K ﹤0.01% 3171
2023
Q2 		$637K Sell
30,448
-179,705
-86% -$3.74M ﹤0.01% 3123
2023
Q1 		$4.44M Buy
210,153
+190,006
+943% +$4.73M ﹤0.01% 2276
2022
Q4 		$513K Sell
20,147
-56,244
-74% -$1.31M ﹤0.01% 3252
2022
Q3 		$1.84M Buy
76,391
+53,856
+239% +$1.21M ﹤0.01% 2673
2022
Q2 		$434K Buy
22,535
+4,779
+27% +$79.6K ﹤0.01% 3397
2022
Q1 		$308K Buy
17,756
+148
+0.8% +$2.49K ﹤0.01% 3626
2021
Q4 		$386K Sell
17,608
-2,385
-12% -$44.1K ﹤0.01% 3499
2021
Q3 		$383K Buy
19,993
+2,276
+13% +$37.9K ﹤0.01% 3546
2021
Q2 		$305K Buy
17,717
+8,069
+84% +$148K ﹤0.01% 3625
2021
Q1 		$216K Sell
9,648
-302,815
-97% -$6.84M ﹤0.01% 3662
2020
Q4 		$6.95M Buy
312,463
+247,025
+377% +$5.12M ﹤0.01% 2006
2020
Q3 		$966K Buy
+65,438
New +$997K ﹤0.01% 2835
2020
Q2 		– Sell
-60,152
Closed -$660K – 3683
2020
Q1 		$660K Buy
+60,152
New +$564K ﹤0.01% 2939

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Invesco's SNDX Position: Q1 2026 in Review

Invesco increased its Syndax Pharmaceuticals (SNDX) stake by 57% in Q1 2026, buying an estimated $2M and bringing the position to 252,761 shares worth $5.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2114.

Invesco first reported a position in SNDX in Q1 2020 and has held it in 24 quarters since. The position peaked at $6.95M in Q4 2020. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Invesco held 252,761 shares of Syndax Pharmaceuticals worth $5.9M as of Q1 2026.
  • Invesco bought 92,236 Syndax Pharmaceuticals shares in Q1 2026, an estimated $2M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2114 holding.
  • Invesco first reported a position in Syndax Pharmaceuticals in Q1 2020 and has held it in 24 quarters since.
  • Invesco's Syndax Pharmaceuticals position peaked at $6.95M in Q4 2020.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.